Sean Tucker - Vaxart Chief Scientific Officer
| VXRT Stock | USD 0.59 0.01 1.67% |
Executive
Dr. Sean N. Tucker serves as Chief Scientific Officer of the company. From March 2004 to February 2010, Dr. Tucker served as our Vice President of Research and Director of Immunology. Prior to this, Dr. Tucker numerous scientific and engineering roles at various biotechnology companies since 2018.
| Age | 56 |
| Tenure | 6 years |
| Address | 170 Harbor Way, South San Francisco, CA, United States, 94080 |
| Phone | 650 550 3500 |
| Web | https://vaxart.com |
Sean Tucker Latest Insider Activity
Tracking and analyzing the buying and selling activities of Sean Tucker against Vaxart stock is an integral part of due diligence when investing in Vaxart. Sean Tucker insider activity provides valuable insight into whether Vaxart is net buyers or sellers over its current business cycle. Note, Vaxart insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vaxart'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Sean Tucker few days ago Acquisition by Sean Tucker of 45000 shares of Vaxart subject to Rule 16b-3 | ||
Sean Tucker over three months ago Acquisition by Sean Tucker of 205000 shares of Vaxart at 0.78 subject to Rule 16b-3 | ||
Sean Tucker over a year ago Acquisition by Sean Tucker of 45000 shares of Vaxart subject to Rule 16b-3 |
Vaxart Management Efficiency
The company has return on total asset (ROA) of (0.3968) % which means that it has lost $0.3968 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9166) %, meaning that it created substantial loss on money invested by shareholders. Vaxart's management efficiency ratios could be used to measure how well Vaxart manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.94 in 2024. Return On Capital Employed is likely to gain to -1.01 in 2024. At this time, Vaxart's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 150.6 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 2.8 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Erika Trahan | Novavax | N/A | |
| Jeffrey Skolnik | Inovio Pharmaceuticals | N/A | |
| E MBA | Inovio Pharmaceuticals | N/A | |
| Dan CPA | Co Diagnostics | N/A | |
| PE MBA | Inovio Pharmaceuticals | N/A | |
| Christopher Thurston | Co Diagnostics | N/A | |
| Kristi Sarno | Ibio Inc | N/A | |
| CMA CPA | Ocugen Inc | N/A | |
| Kristen Craft | Ocugen Inc | N/A | |
| Ivory Chang | Co Diagnostics | N/A | |
| Peter Kies | Inovio Pharmaceuticals | 61 | |
| Seth Egan | Co Diagnostics | N/A | |
| Ian Watkins | Novavax | 61 | |
| Elaine OHara | Novavax | 56 | |
| Mayuranki Almaula | Co Diagnostics | N/A | |
| David MD | Inovio Pharmaceuticals | N/A | |
| Jyothy MS | Ocugen Inc | N/A | |
| John JD | Ocugen Inc | N/A | |
| CMI MD | Ocugen Inc | N/A | |
| Arun Upadhyay | Ocugen Inc | 41 | |
| JD Esq | Novavax | 53 | |
Management Performance
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.4 |
Vaxart Inc Leadership Team
Elected by the shareholders, the Vaxart's board of directors comprises two types of representatives: Vaxart inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vaxart. The board's role is to monitor Vaxart's management team and ensure that shareholders' interests are well served. Vaxart's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vaxart's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rajesh Kapoor, Senior Quality | ||
| Shaily Garg, Senior Management | ||
| Brant Biehn, Sr Operations | ||
| Cezar MBA, Pres CEO | ||
| Sarah Khan, VP Resources | ||
| Phillip Lee, Principal CFO | ||
| Steven Lo, CEO President | ||
| James MD, Chief Officer | ||
| Michael Finney, Interim Director | ||
| Fuad Ahmad, Interim Officer | ||
| CPA MBA, Consultant | ||
| Dr Stapleton, Chief Officer | ||
| Sean Tucker, Chief Scientific Officer | ||
| Edward Berg, Senior Counsel |
Vaxart Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vaxart a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (2.54) % | ||||
| Current Valuation | 96.48 M | ||||
| Shares Outstanding | 227.48 M | ||||
| Shares Owned By Insiders | 0.87 % | ||||
| Shares Owned By Institutions | 17.80 % | ||||
| Number Of Shares Shorted | 11.46 M | ||||
| Price To Book | 2.00 X | ||||
| Price To Sales | 9.67 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.